About Marinomed Biotech AG

Company Description

Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline and globally marketed therapeutics. The Company develops innovative patent-protected products in the therapeutic areas immunology and virology based on the platform Marinosolv® and the virus-blocking activity of iota-carrageenan. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The virology segment includes Carragelose®-based over-the-counter (OTC) products to prevent and treat respiratory viral infections that are partnered in more than 40 countries. Marinomed also develops drugs for other serious viral infectious diseases based on iota carrageenan.

Year founded

2006

Served area

Worldwide

Headcount

37

Headquarters

Hovengasse 25, 2100 Korneuburg – Austria

Shareholder information

Shares outstanding

1,496,287

IPO

Dec. 4, 2018

Stock exchange(s)

Wiener Börse

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.